Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of its HPV vaccine, Gardasil, to reach $11 billion by 2030. The result ...

Merck on Tuesday issued full-year 2025 revenue guidance that fell short of Wall Street's expectations. The company said that sales range reflects a decision to halt shipments of Gardasil, a ...

Say hello to lifetime language learning Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $15.6 billion and adjusted earnings of $1.72 per ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other best vaccine stocks to buy now. What Will Trump’s Tariffs Mean for the Pharma Industry?

Merck MRK0.18%increase; green up pointing triangle shares tumbled more than 11% Tuesday morning after the drugmaker gave 2025 revenue guidance that fell short of analyst expectations and said it ...

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with overall 7% growth for the year. Shares fell more than 10% as Merck ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...